Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
Currently, Allergan plc has a PEG ratio of 1.55 compared to the Medical - Generic Drugs industry's PEG ratio of 0.99.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AGN 145.81 +1.56(1.08%)
Will AGN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for AGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGN
Aurinia Completes Final Patient Treatment in Dry Eye Study
Satsuma Plunges on Disappointing Data on Migraine Treatment
AGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Coronavirus-Led Threats to MedTech That May Linger
Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug
Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates
Other News for AGN
No Record found.